Nuclear pleomorphism, a strong prognostic factor in axillary node-negative small invasive breast cancer

[1]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[2]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[3]  C K Osborne,et al.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.

[4]  William H. Hartmann,et al.  The World Health Organization Histological Typing of Breast Tumors—Second Edition , 1982 .

[5]  H. Bingham.  Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4) , 1985 .

[6]  M. Stierer,et al.  Nuclear polymorphism — a prognostic parameter to evaluate local recurrence of female breast cancer , 1990, Breast Cancer Research and Treatment.

[7]  V. de Vita.  Breast cancer therapy: exercising all our options. , 1989, The New England journal of medicine.

[8]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[9]  I D Bross,et al.  Cancer of the breast: Size of neoplasm and prognosis , 1969, Cancer.

[10]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[11]  T. Landberg,et al.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. , 1988, BMJ.

[12]  S. Hellman,et al.  Are prognostic factors for local control of breast cancer treated by primary radiotherapy significant for patients treated by mastectomy? , 1986, Cancer.

[13]  J. Harris,et al.  Observations on survival curve analysis with particular reference to breast cancer treatment , 1986, Cancer.

[14]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[15]  N. Keiding,et al.  Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. , 1987, Cancer research.

[16]  S. Friedman,et al.  Nuclear characteristics as indicators of prognosis in node negative breast cancer patients , 1989, Breast Cancer Research and Treatment.

[17]  J. Russo,et al.  Predictors of recurrence and survival of patients with breast cancer. , 1987, American journal of clinical pathology.

[18]  B. V. Pedersen,et al.  Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low‐risk carcinomas from a multicenter trial , 1987, Cancer.

[19]  K. Zedeler.  Assessment and presentation of survival experience in the Danish Breast Cancer Cooperative Group. , 1988, Acta oncologica.

[20]  W. McGuire,et al.  Role of steroid hormone receptors as prognostic factors in primary breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[21]  S Friedman,et al.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  R. Gelber,et al.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.

[24]  G. Bonadonna,et al.  Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients , 1978, Cancer.

[25]  Fisher Er.  Prognostic and therapeutic significance of pathological features of breast cancer. , 1986 .

[26]  V. Devita.  Breast Cancer Therapy: Exercising All Our Options , 1989 .

[27]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[28]  S Hellman,et al.  Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Glick.  Meeting highlights: adjuvant therapy for breast cancer. , 1988, Journal of the National Cancer Institute.

[30]  M. Stierer,et al.  Histologic grading and subfactor analysis as prognostic parameters in patients with breast cancer. , 1990, Journal of the National Cancer Institute.

[31]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast and bowel projects (NSABP) prognostic discriminants for 8‐year survival for node‐negative invasive breast cancer patients , 1990, Cancer.

[32]  B. Fisher,et al.  Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4) X. Discriminants for tenth year treatment failure , 1984, Cancer.

[33]  W. McGuire.  Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[34]  N. Wolmark,et al.  Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. , 1975, Surgery, gynecology & obstetrics.

[35]  Norman Wolmark,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project , 2004, Cancer.

[36]  M. Stierer,et al.  Influence of early diagnosis on prognosis of recurrent breast cancer , 1989, Cancer.

[37]  S Friedman,et al.  Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.